BioSpace News Archive

The debut of a new U.S. based global biotechnology company, Vaxxinity, will take place at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, at 9:50 a.m. EST.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, and UT Southwestern Medical Center (UTSW) today announced the launch of an innovation fund

KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the company is participating in BIO @ JPM and Fierce JPM Week 2021

Nuvo Pharmaceuticals Inc. (TSX: MRV) (OTCQX: MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian focused healthcare company with global reach and a diversified portfolio of commercial products, today announced the commercial launch of NeoVisc+ 2 mL and NeoVisc ONE 4 mL in Canada

Cytovia Therapeutics, an emerging biopharmaceutical company focusing on Natural Killer cells in cancer, announced today that it has signed a licensing agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to apply its gene-edited iPSC-derived NK cell technology to develop GPC3 CAR NK cell therapeutics

Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported preliminary unaudited revenue results for the quarter and full year ended December 31, 2020.

Sesen Bio and Qilu Pharmaceutical Announce IND Application for Vicineum ™ Accepted for Review by the National Medical Products Administration in China Clinical trial expected to be initiated shortly after NMPA approval of the IND Sesen Bio to receive $3M milestone payment upon IND approval

This additional non-dilutive financing will support development program for lechlemer for the indication of the symptomatic relief of diarrhea and dehydration in cholera patients REMINDER: Jaguar-hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time. Webcast registration and participation link appears below

SleepScore Labs, the Sleep Science Company behind the world’s most comprehensive suite of data-backed sleep solutions, continues to lead the way in applied sleep research, highlighted with their latest product validation study of EyeJust Blue Light Filtering Screen Protectors for iPads and MacBooks.

Company Expects to Exceed Previously Announced Guidance Across All Key Metrics; Provides Full Year 2021 Guidance and Updates Long-Term Targets 2020 Total Product Bookings Expected to be Approximately $1.00 Billion and 2020 Revenues Expected to be $890 Million-$892 Million Increased Full Year 2021 Preliminary Revenue Guidance to $1.085 Billion-$1.105 Billion